Skip to main content
WCGIC 2023 Main banner
Back

Session IX: Hepatocellular Cancer

SO-14: Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup

Thursday, June 29, 2023
16:00 – 16:08 CEST
Location: Auditorium A, Level 0

    Abstract Presenter(s)

  • Arndt Vogel, MD

    Medizinische Hochschule Hannover
    Hannover, Germany